Last reviewed · How we verify
Duratocin — Competitive Intelligence Brief
phase 1
Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V2 receptor
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Duratocin (Duratocin) — Dongyu Wang.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Duratocin TARGET | Duratocin | Dongyu Wang | phase 1 | Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V2 receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Duratocin — Competitive Intelligence Brief. https://druglandscape.com/ci/duratocin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing